TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03085732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation with Saline Solution
Description: During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
Study: NCT01120327

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine
Study: NCT00673673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
Study: NCT02501356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ISOThrive Supplement
Description: Consumption of ISOThrive supplements for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ISOThrive Supplement
Description: Consumption of ISOThrive supplements for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
Study: NCT04256746

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Boiled Rice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+0.37 gr mulberry fruit powdered extract

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+0.75 gr mulberry fruit powdered extract

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+1.12 gr mulberry fruit powdered extract

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+1.50 gr mulberry fruit powdered extract
Study: NCT00894855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biometric feedback
Description: Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biometric feedback
Description: Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dermatologist skin exam
Description: Full body skin exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dermatologist skin exam
Description: Full body skin exam.
Study: NCT03221049

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Study: NCT00750243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-NS001
Description: 1200 mg b.i.d. p.o. for 7.5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn®
Description: 500 mg b.i.d. p.o. for 7.5 days
Study: NCT04184947

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
Study: NCT01954277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Eletroacupuncture performed using acupuncture needles.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Sham
Description: Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
Study: NCT02795858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin Analog
Study: NCT01135784

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MIGRA-ZEN RELIEF PLUS
Description: one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
Study: NCT04256746

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice Porridge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice porridge+1.50 gr mulberry fruit powdered extract
Study: NCT04440917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, iv, on day 1, 15, 29, 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250 mg po, qd, 28 days as a cycle, 2 cycles in total
Study: NCT00758862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% TD1414 Cream
Description: Application 3 times daily for 7 days
Study: NCT00751101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
Study: NCT01135784

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Migrazen relief plus
Description: 2 capsule dose per 24 hours for 90 days
Study: NCT04341337

Intervention type: OTHER
Intervention: interview
Description: questionnaire about ethics in surgery
Study: NCT00185757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytokine Induced Killer Cells
Description: CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
Study: NCT01983735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TELMINUVO Tab. (80/2.5mg)
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TELMINUVO Tab. (80/5mg)
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 2.5mg
Description: * S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 5mg
Description: * S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks.
Study: NCT02236858

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPA Air Cleaner
Description: Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HEPA Air Cleaner
Description: Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
Study: NCT01932021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adipose tissue grafting
Study: NCT04565587

Intervention type: OTHER
Group type: OTHER
Intervention: Xanthan-gum based thickener
Description: Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
Study: NCT01487720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
Study: NCT06251349

Intervention type: RADIATION
Intervention: Radiation
Description: Single dose radiation with 7-8 Gy

Intervention type: DRUG
Intervention: Diclofenac
Description: postoperative treatment with diclofenac to prevent HO
Study: NCT04469751

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: invasive blood pressure monitoring
Description: radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
Study: NCT01206595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKY0402
Description: Single dose of SKY0402 administered as a nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Single dose of 125 mg administered as a nerve block
Study: NCT00447213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patient specific, injected, daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patient specific, injected, daily, 24 weeks
Study: NCT02873260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV-TV005
Description: TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN3Δ30
Description: Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3Δ30
Description: Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
Study: NCT00447213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals,12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals,12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable Insulin
Description: Patient specific dose,injected, before meals, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable Insulin
Description: Patient specific dose,injected, before meals, 12 weeks
Study: NCT01475292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 50 ug administered via a nebuliser once daily for 14 days
Study: NCT01647256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nikkomycin Z
Description: Capsule, 500 mg, single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nikkomycin Z
Description: Capsule, 500 mg, single-dose
Study: NCT01594372

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy with sacropexy
Description: Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral colposuspension
Description: Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
Study: NCT04015141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Oral Suspension
Description: Perampanel oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Tablet
Description: Perampanel tablet.
Study: NCT02885168

Intervention type: DEVICE
Group type: OTHER
Intervention: Near-infrared spectroscopy (NIRS)
Description: After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS)
Description: After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.

Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine
Description: Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Analysis of inflammation and cellular adhesion markers and free radicals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Analysis of inflammation and cellular adhesion markers and free radicals
Study: NCT03400982

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bone densitometry measurement
Description: Bone densitometry and measurement of body composition
Study: NCT02658097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Pembrolizumab by IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Fraction Radiation Therapy
Description: 8Gy radiation therapy will be given in a single fraction on the first day of treatment
Study: NCT02859818

Intervention type: OTHER
Group type: OTHER
Intervention: therapeutic education program
Study: NCT03143491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Description: 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
Study: NCT03631355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
Study: NCT02352584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110A(Quadrivalent)
Description: GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GC Flu(Trivalent)
Description: GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GC3110A(Trivalent)
Description: GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
Study: NCT02533791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
Description: one dose, 4×10\^10vp/1ml per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
Description: two doses, 0.8×10\^11vp/1ml per dose, with one dose to each arm at the same time
Study: NCT04016051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Syrup (187.5 mg)
Description: Clarithromycin Syrup 3.75 ml (187.5 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Syrup (250 mg)
Description: Clarithromycin Syrup 5 ml (250 mg).
Study: NCT02367014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (low dose)
Description: elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Study: NCT02536339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT02367014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (intermediate dose)
Description: elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (high dose)
Description: elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
Study: NCT02533791

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02367014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
Study: NCT01182168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Description: Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
Study: NCT04554485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
Study: NCT03373474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local distribution points association
Description: Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm.
Study: NCT02536339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Study: NCT04604847

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood test
Description: blood test to explore BDNF level
Study: NCT03295526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph nodes debulking surgery.
Description: Radical hysterectomy and selective enlarged lymph node dissection
Study: NCT00468000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM Injection
Study: NCT03780712

Intervention type: OTHER
Intervention: Non applicable
Description: No intervention as it is an observational study